← Back to Clinical Trials
Recruiting NCT06518785

NCT06518785 Ultrasound Neuromodulation of the Brain for Alcohol Use Disorder

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06518785
Status Recruiting
Phase
Sponsor University of California, San Francisco
Condition Alcohol Use Disorder
Study Type INTERVENTIONAL
Enrollment 25 participants
Start Date 2025-01-07
Primary Completion 2030-09

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Low Intensity Focused Ultrasound

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 25 participants in total. It began in 2025-01-07 with a primary completion date of 2030-09.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to examine the effects of Low-Intensity Focused Ultrasound (LIFU) on brain activity in patients with alcohol use disorder.

Eligibility Criteria

Inclusion Criteria: 1. Male or female ≥ 18 years of age. 2. Documentation of an AUD diagnosis per DSM-5 criteria as evidenced by problematic pattern of alcohol use leading to clinically significant impairment or distress, as manifested by at least two of the DSM-5 criteria, occurring within a 12-month period. 3. Be willing to undergo a brain MRI and follow study protocol. Exclusion Criteria: 1. Pregnant or breastfeeding. 2. Presence of a condition or abnormality that would compromise the safety of the patient or the quality of the data. 3. Non-English speaking. 4. Other investigational AUD treatments. 5. Primary psychosis, Bipolar I, or severe personality disorder. 6. Active suicidality or history of suicide attempt in the past 5 years. 7. Cognitive impairment (MoCA \<24) 8. Significant medical or neurological disease, or life expectancy \<12 mos. 9. Significant brain abnormality on brain imaging. 10. Any MRI exclusion criteria.

Contact & Investigator

Central Contact

Catherine Borror, BS, CCRP

✉ TN2Lab@ucsf.edu

📞 415-514-6551

Principal Investigator

Khaled Moussawi, MD, PhD

PRINCIPAL INVESTIGATOR

University of California, San Francisco

Frequently Asked Questions

Who can join the NCT06518785 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Alcohol Use Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06518785 currently recruiting?

Yes, NCT06518785 is actively recruiting participants. Contact the research team at TN2Lab@ucsf.edu for enrollment information.

Where is the NCT06518785 trial being conducted?

This trial is being conducted at San Francisco, United States.

Who is sponsoring the NCT06518785 clinical trial?

NCT06518785 is sponsored by University of California, San Francisco. The principal investigator is Khaled Moussawi, MD, PhD at University of California, San Francisco. The trial plans to enroll 25 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology